Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Type 2 Diabetes
Interventions
OTHER

Lixisenatide

"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."

OTHER

Placebo

Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.

Trial Locations (1)

GU2 7WG

University of Surrey FHMS Diabetes and Metabolic Medicine, Guildford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of Surrey

OTHER